Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield

JHVEPhoto Overview Pfizer (NYSE:PFE) (NEOE:PFE:CA) has struggled to gain any sort of recovery momentum since it suffered losses in revenue coming off the tail end of the pandemic. In addition, the upcoming patent expiries seem to be a source of concern for many investors here as we try to figure out how PFE will whether that storm. I previously covered PFE back in January and rated it a Strong Buy, and the total return since then has been mostly flat. Data by YCharts I wanted to take this opportunity to ...